Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
01/04/18
Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
- Microbiome analyses demonstrate engraftment of SER-287-derived bacteria; microbiome compositional changes correlate with clinical remission - - SER-287 engraftment maintained four weeks after completion of dosing - - Company to discuss proposed SER-287 development plan with FDA and intends to initiate next clinical trial in mid-2018 - - FDA granted SER-287 Orphan Drug designation for treatment of pediatric UC patie... 
01/04/18
Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT. A live audio webcast of the presentation and breakout question and answer session will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become av... 
12/04/17
Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 4, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to microbiome therapeutic candidate SER-287 for the treatment of Ulcerative Colitis (UC) in pediatric patients. Orphan Drug Designation provides incentives designed to advance drug development for rare diseases or conditions that affect fewer than ... 
EventsMore
Webcast ImageWebcast
Seres Therapeutics, Inc. at the 36th Annual JP Morgan Healthcare Conference (Replay)
01/11/18 at 8:30 a.m. PT
Seres Therapeutics, Inc. at the 36th Annual JP Morgan Healthcare Conference
Thursday, January 11, 2018 8:30 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Seres Therapeutics, Inc. at the 36th Annual JP Morgan Healthcare Conference Q&A Session (Replay)
01/11/18 at 12:00 p.m. ET
Seres Therapeutics, Inc. at the 36th Annual JP Morgan Healthcare Conference Q&A Session
12:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$10.20
0.00 (0.00%)
01/17/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.